NCT06665412View on ClinicalTrials.gov

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

RecruitingOBSERVATIONAL
Enrollment

168

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Phase Ph+ Chronic Myeloid Leukemia
Interventions
DRUG

Radotinib Hydrochloride

200mg BID, every day up to 12months

Trial Locations (2)

14068

RECRUITING

Hallym University Sacred Heart Hosptial, Anyang-si

42601

NOT_YET_RECRUITING

Keimyung University Daegu Dongsan Hospital, Daegu

All Listed Sponsors
lead

Il-Yang Pharm. Co., Ltd.

INDUSTRY